Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2 | P11137 | 14/20 | 0.61 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.56 |
| ▸ | TUBB | P07437 | 2/20 | 0.56 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.56 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.56 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.56 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.56 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.56 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.56 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.56 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.56 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.56 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.56 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.56 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.56 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-737126 SCHEMBL31654105 | 1.00 | MAP2 (0.61) | MAP2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL8938304 | 0.92 | MAP2 (0.59) | MAP2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL8938370 | 0.91 | TUBB4A (0.61) | MAP2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL8687789 | 0.90 | MAP2 (0.59) | MAP2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL2879576 | 0.89 | TUBB4A (0.53) | MAP2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL8938309 | 0.88 | MAP2 (0.58) | MAP2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL8938269 | 0.88 | MAP2 (0.51) | MAP2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4410863 | 0.86 | KDM4E (0.63) | MAP2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL2881831 | 0.86 | TUBB4A (0.51) | MAP2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL2879565 | 0.86 | TUBB4A (0.51) | MAP2TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 766 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4133605-B1 | DEVICE AND METHOD FOR CANCELLING INTERFERENCE | HUAWEI TECH CO LTD (CN) | 2026-05-20 | — | — | EP | claimed |
| CN-222979865-U | Two-dimensional metallographic microscope | 东莞市贝特森精密仪器有限公司 | 2025-06-13 | — | — | CN | claimed |
| CN-118921656-A | Privacy protection wireless sensing method and system based on CSI confusion | 东南大学 | 2024-11-08 | — | — | CN | claimed |
| CN-111782344-B | Method, system and host for providing password resources | 北京数字认证股份有限公司 | 2024-06-21 | — | — | CN | claimed |
| CN-117970301-A | Equipment distance measuring method based on WiFi channel state information | 西安电子科技大学 | 2024-05-03 | — | — | CN | claimed |
| CN-117492828-A | Binary translation debugging method and device, computing equipment and storage medium | 统信软件技术有限公司 | 2024-02-02 | — | — | CN | claimed |
| CN-114401112-B | Bypass deployment real-time deep packet detection method for malicious traffic encrypted by TLS | 内蒙古农业大学 | 2023-11-03 | — | — | CN | claimed |
| US-20230119655-A1 | NOVEL CRISPR-CAS SYSTEMS FOR GENOME EDITING | PIONEER HI-BRED INTERNATIONAL, INC. (US) | 2023-04-20 | — | — | US | claimed |
| EP-4133605-A1 | DEVICE AND METHOD FOR CANCELLING INTERFERENCE | Huawei Technologies Co., Ltd. (CN) | 2023-02-15 | — | — | EP | claimed |
| WO-2022268975-A1 | METHOD FOR TREATING A PLANT | RHODIA OPERATIONS (FR) | 2022-12-29 | — | — | WO | claimed |
| EP-1791537-A1 | 3-ARYLTHIOINDOLE-2-CARBOXAMIDE DERIVATIVES AND ANALOGS THEREOF AS INHIBITORS OF CASEIN KINASE I | Aventis Pharmaceuticals, Inc. (US) | 2007-06-06 | — | — | EP | claimed |
| WO-2006023590-A1 | 3-ARYLTHIOINDOLE-2-CARBOXAMIDE DERIVATIVES AND ANALOGS THEREOF AS INHIBITORS OF CASEIN KINASE Iϵ | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-02 | — | — | WO | claimed |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | claimed |
| US-5527819-A | TREATING AIDS | MERCK & CO., INC. (US) | 1996-06-18 | — | — | US | claimed |
| EP-0686148-A4 | INHIBITORS OF HIV REVERSE TRANSCRIPTASE | MERCK & CO INC (US) | 1996-02-07 | — | — | EP | claimed |
| EP-0686148-A1 | INHIBITORS OF HIV REVERSE TRANSCRIPTASE | MERCK & CO. INC. (US) | 1995-12-13 | — | — | EP | claimed |
| EP-0678508-A1 | Indoles as inhibitors of HIV reverse transcriptase | MERCK & CO. INC. (US) | 1995-10-25 | — | — | EP | claimed |
| WO-1994019321-A1 | INHIBITORS OF HIV REVERSE TRANSCRIPTASE | MERCK & CO., INC. (US) | 1994-09-01 | — | — | WO | claimed |
| WO-1993005020-A1 | INDOLES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | MERCK & CO., INC. (US) | 1993-03-18 | — | — | WO | claimed |
| EP-0530907-A1 | Indoles as inhibitors of HIV reverse transcriptase | MERCK & CO. INC. (US) | 1993-03-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | MAP2 4296/4885TUBB4A 4545/4885TUBB 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.